Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2000-03-08
2002-08-13
Jones, Dwayne C. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S741000
Reexamination Certificate
active
06433011
ABSTRACT:
FIELD OF INVENTION
This invention relates to treatment for the inhibition or reduction of colon tumorigenesis in a mammal by the administration of a pharmaceutical compound.
BACKGROUND OF INVENTION
Evidence from epidemiological studies suggests an association of consumption of cruciferous vegetables and a reduced risk of colon cancer (31). Although a number of compounds in these vegetables may collectively cause the beneficial effects, there has been a need to identify the exact role of each compound that contributes to the protective effects. Ample data from laboratory animal studies have shown that isothiocyanates (ITCs), one of the major constituents of cruciferous vegetables, are promising chemopreventive agents against cancers at various sites, including lung, esophagus, liver, mammary, and bladder (3, 32, 33). These laboratory results support a potential role of dietary ITCs in reducing risk of certain human cancers. However, it is well known to those of skill in the art that chemopreventive agents affect different tissues differently.
Previously, for example, it has been reported that while phenylhexyl ITC, a synthetic homologue of PEITC, is a potent inhibitor of lung tumorigenesis, it enhanced colon and esophagus tumorigenesis in rats, possibly due to its tissue cytotoxicity at the dose level studied (29, 30). These results illustrate the importance of considering tissue specificity and of choosing the appropriate dose range for specific tissues in chemoprevention studies.
A recent case-control study reported that broccoli consumption is linked to a lowered risk of colon cancer, and the protective effect is especially evident in individuals with a glutathione transferase (GST) M1 null genotype (1). Because GSTs facilitate the conjugation of ITCs resulting in their excretion as the N-acetylcysteine NAC) conjugates via the mercapturic acid pathway, it has been suggested that the ITC compounds in broccoli may play a role in the protection of human colon cancer (2). Sulforaphane (SFN) is the predominant ITC found in broccoli which has been studied for its chemopreventive potential due to its activity in the induction of phase II enzymes involved in carcinogen detoxification and elimination (3). However, so far no animal data is available regarding the effects of SFN on colon tumorigenesis. Several laboratory animal studies have shown that phenethyl ITC (PEITC), a principal constituent in watercress, is a potent chemopreventive agent for cancers of the breast, lung, and esophagus (4, 5, 6). However, there is insufficient data for PEITC on colon cancer.
Considering the natural abundance of SFN and PEITC in broccoli and watercress, respectively, and their potential as chemopreventive agents, it is surprising that little is known about the effects of these agents on colon tumorigenesis. A lower homologue of PEITC, benzyl ITC (BITC) has been shown to inhibit colon tumor incidence in AOM treated rats during the initiation phase, but not during the post-initiation phase (34). Another short-term study, however, has reported that both PEITC and BITC given in the diet at similar dose levels were inactive towards ACF formation, in fact, BITC was found to slightly induce ACF formation (10). By contrast, the present inventors have now demonstrated for the first time that both PEITC and SFN inhibit colonic ACF, independent of whether they are administered before or after carcinogen exposure.
SUMMARY OF THE INVENTION
There is provided in accordance with one embodiment of the invention a method for inhibiting tumor development in a mammal. The method comprises administering to the mammal a pharmacologically effective amount of an isothiocyanate selected from the group consisting of sulforaphane and phenethyl isothiocyanate. The sulforaphane may be isolated from broccoli and the phenethyl isothiocyanate may be isolated from watercress. The isothiocyanate is preferably administered to the mammal as a purified compound, either alone or in a composition with a pharmacologically acceptable carrier, excipient or diluent or with a beverage or foodstuff.
In a preferred embodiment of the invention, the mammal is a human and the isothiocyanate is administered to the human as a dietary supplement. In a preferred treatment regimen, the isothiocyanate is administered to the human in a dosage of between about 0.5 and 12 mg/kg body weight per day.
In another embodiment of the invention there is provided a method for treating colon tumor formation in a mammal in need of such treatment. The method comprises administering to the mammal a pharmacologically effective amount of an isothiocyanate selected from the group consisting of sulforaphane and phenethyl isothiocyanate.
The above and other features and advantages of the invention will be found in the detailed description which follows below.
REFERENCES:
patent: RE36784 (2000-07-01), Cho et al.
O.S. Sohn et al, “Enhancement of Rat Liver Microsomal Metabolism of Azoxymethane to Methylaxoymethanol . . . N-Nitrosodimethylamine”Cancer Researchvol. 47 (1987) pp. 3123-3129.
S. Sugie et al., “Inhibitory Effects of Benzyl Thiocyanate and Benzyl Isothiocyanate on Methylazoxymethanol . . . Carcinogenesis in Rats”Carcinogenesisvol. 15, No. 8 (1994) pp. 1555-1560.
M.J. Iatropoulos et al., “Three Month Toxicity Study of Phenethyl Isothiocyanate in Fischer 344 Rats” American Health Foundation,AHF StudyNo. R-1508, Final Report (1995), pp. 1-182.
Lin, H.J.,, et al (1998)Glutathione transferase null genotype, broccoli, and lower prevalence of colorectal adenomas, Cancer Epidemiol., Biomark.. Prev. 7, 647-652.
Ketterer, B., et al (1998) Dietary isothiocyanates as confounding factors in the molecular epidemiology of color cancer. Cancer Epidemiol., Biomark.. Prev. 7, 647-652.
Zhang, V, et al (1994) Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. Cancer Res. 54 (Suppl.), 1976s-1986s.
Chung, F.L. et al (1992) New potential chemopreventive agents for lung carcinogenesis of tobacco-specific nitrosamine. Cancer Res. 52, 2719s-2722.
McLellan, E.A. et al (1988) Aberrrant crypts: potential preneoplastic lesions, in the murine colon Cancer Res. 51: 5270-5274.
Pretlow, T.P. et al (1992) Aberrant crypts in human colonic mucosa: putativePreneoplastic lesions. J. Cell Biochem 166 (suppl.) 55-52.
Wargovich, M.J. et al (1996) Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. Cancer Epidemiology, Biomarkers and Prev. 5:355-360.
Jiao, D. et al (1997) Chemopreventive activity of thiol conjugates of isothiocyantes for lung tumorigenesis. Carcinogenesis 18: 2143-2147.
Chung, F.L. et al (1997) Chemopreventive potential of thiol conjugates of isothiocyanates for lung tumorigenesis. J. Cell Biochem (suppl.) 27: 76-85.
Kassahun, K., et al (1997) Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: identification of phase 1 metabolites and glutathione conjugates. Chem. Res. Toxicol. 10: 1228-1233.
Jiao, D., et al (1996) Inhibition of N-nitrosodimethylamine demethylase in rat and human liver microsomes by isothiocyanates and their glutathione, L-cysteine, and N-acetyl-L-cysteine conjugates. Chem. Res. Toxicol., vol. 9 (6) : 932-938.
Conway, C.C et al (1996) Inhibition of rat liver cytochrome P450 Isozymes by isothiocyanates and their conjugates: A structure-activity relationship study. Carcinogenesis, 17: 2423-2427.
Chung, F.L., et al. Chemoprevention of lung carcinogenesis by aromatic isothiocyanates. In: Cancer chemoprevention, CRC Press Inc. pp227-245, 1992.
Sugie, S. et al (1994) Inhibitory effects of benzyl thiocyanate and benzyl isothiocyanate on methylazoxymethanol acetate-induced intestina carcinogenesis in rats. Carcinogenesis 15: 1555-1560.
Wattenberg, L.W. “Inhibition of Carcinogenic Effects of Polycyclic Hydrocarbons by Benzyl Isothiocyanate and Related Compounds” J. Natl. Cancer Inst., 58, (1977) pp 395-398.
Stoner, G.D., et al. “Inhibitory Effects of Phenethyl Isothiocyanate on N-Nitrosobenzylmethylamine Carcinogenesis . . . ” Cancer Res., 51, (1991) pp 2063-20
Chung Fung-Lung
Conaway C. Clifford
Reddy Bandaru
American Health Foundation
Delacroix-Muirheid C.
Jones Dwayne C.
Ladas & Parry
LandOfFree
Method for inhibiting formation of aberrant crypt foci in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting formation of aberrant crypt foci in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting formation of aberrant crypt foci in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2925557